TT-223

TT-223 is a gastrin analogue and cholecystokinin (CCK) receptor agonist that was developed for the treatment of type 2 diabetes. It was initially developed by Transition Therapeutics and later licensed to Eli Lilly. The drug was designed to improve glycemic control in patients with type 2 diabetes, either as monotherapy or in combination with other agents such as GLP-1 analogues. Clinical trials included Phase 2 studies evaluating its efficacy and safety, both alone and in combination with GLP-1 analogues. However, results showed that while TT-223 demonstrated some efficacy during development, it did not provide significant additional benefit over existing therapies for diabetes. As a result, further development of TT-223 for type 2 diabetes has been discontinued[1][3][4][5].